Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
The rivalry between enterprise software makers Snowflake and Databricks intensified amid the emergence of generative ...
Tesla stock fell Monday amid a fresh TSLA price-target cut as the EV giant's favorability has slumped. TSLA stock dived over ...